Why Attend
The market value for cell therapies is expected to triple in size by 2025 to $8.21 bn, with investment also having increased by 64% since 2017 to $7.6 bn. Cell therapies have a huge commercial potential however scaled manufacturing, automation, logistics, regulation, and quality control continue to be limiting factors. Before cell therapies can make a mainstream clinical impact, patient access increased and truly reach their commercial potential, these obstructions need to be improved.
The Vein-to-Vein Congress will gather manufacturing, operations, site managers and logistical heads from both Biotechs and pharmaceutical companies to address these bottlenecks and facilitate the commercial manufacture of cell therapies.
As the cell therapy industry shifts from manual to automated manufacturing, the Vein-to-Vein Congress will discuss the measures that leading companies have put in place to streamline their manufacturing process, scale-up over time and ensure a water-tight supply chain with tracking and trackability from cell collection to patient.
The Speakers
Ali Mohamed
Markwin Velders
Dr David Sourdive, PhD
David Sourdive, Ph.D., is a co-founder of Cellectis and joined the Board of Directors in 2000. Dr. Sourdive holds the position of Executive Vice President, Technical Operations, with the mission to develop the Company’s industrial and technological basis as well as to deploy its operations in the pharmaceutical arena. Dr. Sourdive combines a strong scientific expertise with experience in managing industrial programs bringing innovative technologies to industrial fruition. He served as Executive Vice President, Corporate Development, from 2008 to 2016. In addition to his role at Cellectis, Dr. Sourdive has also served on the board of directors of the Mediterranean Institute for Life Sciences. David Sourdive graduated from École Polytechnique, received his Ph.D. in molecular virology at Institut Pasteur and completed a research fellowship in the Emory University Department of Microbiology and Immunology. His management training is from the HEC (Challenge +) and his decade-long experience in industrial program management was acquired at the French Department of Defense (DGA) prior to Cellectis’ inception.
Emanuele Ostuni
Fabio Fachin
Niloofar Davoodi
Stefan Wildt
Liesbeth De Jong
Lior Raviv
Louise Bisset
Paul Kemp
Piers Walser
Qasim Rafiq
Volker Huppert
Jasmin Kee
Jean-Pierre Latere Dwan’Isa
Pierre Heimendinger
Sadia L'Bouch
Dr Detlev Parow
Cell Therapy Event Gallery
TESTIMONIALS
WHO WILL BE THERE
Network with industry experts from:
- Big pharma and biotech
- Cell Therapy Academics and clinicians
- Process standardisation - technology/services
- Logistics companies - cell storage/transport
- Service providers - CRO’s, Consultants, Government
Past attendees include:
The Agenda
If you’re working on autologous or allogenic cell therapies, The Vein-to-Vein Congress will cover a diverse range of cell types including NK, CAR-T, stem and placental cells.
The global cell and gene therapy market is projected to surpass $35B by 2026 and with investment in the space increasing 64% in the last two years It’s obvious there’s huge commercial potential. The question is, with the cost of cell therapies at a premium, how can the industry reduce COGS and facilitate a mass role out? There are clear bottlenecks that exist across the industry; scale-up of manufacturing, logistics, raw material supply, regulation and automation of processes are all posing real headaches to the rapidly growing field.
The Vein-to-Vein Congress EU will focus on providing actionable solutions to these bottlenecks through case studies and interactive panel sessions with leaders in cell therapy who’ve been through the same challenges that you’re experiencing. Whether you’re streamlining logistics, scaling and automating manufacturing processes or developing robust raw material supply chains, join 100+ CTOs, COOs, Heads of Manufacturing, QC and Supply Chain who’ve been there and done just that.
Take away actionable insights from a range of cell therapy types including:
· Building an in-house cell therapy manufacturing facility with Markwin Velders of Kite Pharma
· Upscaling manufacturing for clinical and commercial manufacturing with Ali Mohamed of Immatics.
· Ensuring a reliable and traceable supply of quality GMP starting and raw material with David Sourdive of Cellectis.
· Streamlining cell therapy manufacture through automation and integration of instruments with Fabio Fachin of Takeda.
· Establishing end to end accountability of materials and product from vein to vein with Volker Huppert of Glycostem.
Download Agenda
Conference Packages
Sending Your Team? Group Discounts Available!
Applicable for Primary Market, Service Provider and Industry Rates Only. Not available for Academic or ‘Start-Up’ rates
Book a Team of 3+ - Save an Additional 10% Off
Book a Team of 5+ - Save an Additional 15% Off
If you would like to register a team of 3 or more, please email [email protected] for your discount coupon code before registering. PLEASE NOTE: Discounts cannot be combined with Early Bird Pricing or any other discount or offer. If you have any questions about your registration, please call us on +44 (0)20 3696 2920
Expertise Partner
Innovation Partner
Event Partner
PARTNER WITH US
Based on your objectives, we can create bespoke packages designed specifically for you. Opportunities predominantly lie in 3 main categories: Thought Leadership, Branding, and Networking.
Interested in a media partnership?
We'd love to hear from you and how we can support one another to connect with the industry. Contact [email protected]
Venue
Leonardo Royal Hotel London City, 8-14 Cooper’s Row, London, EC3N 2BQ
We are delighted to be returning to London for the Vein-to-Vein Congress EU. The Leonardo Royal Hotel London is very close to Tower Hill station, located in Zone 1.
We have a number of discounted rooms available for the event at the hotel itself:
27 Jan - £159.00 incl VAT & breakfast, single occupancy
28 Jan - £179.00 incl VAT & breakfast, single occupancy
To book call: +44 (0) 161 774 1742
or email: [email protected]
Quote the Block Code: LHKISA270120.
Card details required when making a booking. Rooms are available until 27 December 2019 on the above rate. After this date rates will be subject to availability.
About Kisaco Research
Kisaco Research produces, designs and hosts B2B industry conferences, exhibitions and communities – focused on a specialized selection of topic areas.
Meet industry peers that will help build a career-changing network for life.
Learn from the mistakes of your peers as much as their successes—ambitious industry stalwarts who are happy to share not just what has made them successful so far but also their plans for future proofing their companies.
Note down the inspired insight that will form the foundation for future strategies and roadmaps, both at our events and through our online communities.
Invest both in your company growth and your own personal development by signing up to one of our events and get started.